1
—
In review
Synced today
What it does
Use when deciding which cc-* sub-skill to invoke next, or when sequencing a Cancer Cell (Cell Press) manuscript from scope check through peer-review revision. Routes — it does not replace — the specialized skills.
Skill profile
Keep exploring
More options in Business Ops.
Claude Code · Codex · OpenClaw
Python
Updated 7/30/2026
Agent compatibility
Compatibility has not been reviewed for this listing yet. Check the publisher documentation before installing.
Installation
npx skills add https://github.com/thedixitjain/the-mega-skill-library --skill cc-workflowReview source code and installation permissions before adding third-party tools to an agent.
cc-workflow is organized in the Business Ops category. Compare its source, install method, and compatibility before adding it to your workflow.
Third-party agent tools may access source code, credentials, or browser sessions. Read the source documentation and use the minimum permissions needed.
npx skills add https://github.com/thedixitjain/the-mega-skill-library --skill cc-workflowSKILL.md
---
name: cc-workflow
description: "Use when deciding which cc-* sub-skill to invoke next, or when sequencing a Cancer Cell (Cell Press) manuscript from scope check through peer-review revision. Routes — it does not replace — the specialized skills."
category: general-purpose
source_repo: brycewang-stanford/Awesome-Journal-Skills
source_path: "Cancer-Cell-Skills/skills/cc-workflow/SKILL.md"
source_url: https://github.com/brycewang-stanford/Awesome-Journal-Skills/blob/HEAD/Cancer-Cell-Skills/skills/cc-workflow/SKILL.md
---
# Cancer Cell Workflow (cc-workflow)
## Overview
This is the router. It does not replace any specialized skill — it tells you **which cc-* skill to use at your current stage** of a Cancer Cell (Cell Press) molecular / translational oncology manuscript.
Default assumption: unless the user says otherwise, treat the target as **Cancer Cell**, where the bar is a clear molecular mechanism validated across orthogonal systems (cells + in vivo + ideally human data), reported with STAR Methods rigor, framed for translational relevance without overclaiming.
## When to trigger
- The user asks "what should I do next?"
- A draft arrives and you must diagnose the current bottleneck
- Work is thrashing between experiments, figures, and writing
- A decision letter / reviewer reports arrive and you must switch into revision mode
## Routing table
| Current symptom | Next skill |
|------------------------------------------------------------------------|-----------------------------|
| Unsure whether the story is a Cancer Cell paper at all | `cc-scope-fit` |
| Mechanism rests on one system (cells only / no in vivo / no human data) | `cc-study-design` |
| Controls, replicates, randomization, or blinding are unclear | `cc-study-design` |
| No Key Resources Table; cell lines unauthenticated; antibodies unvalidated | `cc-reporting-standards` |
| `n` undefined, pseudo-replication risk, wrong test, error bars unlabeled | `cc-statistics` |
| Representative images with no quantification; multi-panel figure messy | `cc-figures-tables` |
| Need Summary / Highlights / eTOC blurb / graphical abstract | `cc-structured-abstract` |
| Missing IACUC/IRB approval, consent, biosafety, or data-availability statement | `cc-ethics-registration` |
| Prose overclaims; Results read like a lab notebook; weak Discussion | `cc-writing-style` |
| Need a cover letter framing fit and significance | `cc-cover-letter` |
| About to submit and need a final preflight | `cc-submission` |
| Reviewer reports arrived; need a point-by-point response | `cc-peer-review-revision` |
## Default order
1. `cc-scope-fit` — confirm mechanism + translational relevance before investing more
2. `cc-study-design` — design / audit orthogonal validation, controls, replicates, in vivo rigor
3. `cc-reporting-standards` — STAR Methods, Key Resources Table, authentication, RRIDs
4. `cc-statistics` — define `n`, pick tests, correct for multiplicity, label error bars
5. `cc-figures-tables` — multi-panel mechanistic figures with quantification + image integrity
6. `cc-structured-abstract` — Summary, Highlights, eTOC blurb, graphical abstract
7. `cc-ethics-registration` — approvals, consent, biosafety, data-deposition statements
8. `cc-writing-style` — Cell Press prose and claim calibration (polish stage)
9. `cc-cover-letter` — significance / fit / suggested reviewers
10. `cc-submission` — pre-submission preflight
11. `cc-peer-review-revision` — after reviewer reports
> `cc-writing-style` and `cc-structured-abstract` are **late-stage polish** — do not finalize them while the mechanism or in vivo validation is still missing.
## Decision shortcuts
- "It's only in cell lines" → `cc-study-design` (add in vivo / human validation)
- "Reviewers will ask if the cell line is authenticated" → `cc-reporting-standards`
- "I used n=3 wells from one experiment" → `cc-statistics` (pseudo-replication)
- "I have a beautiful blot but no densitometry" → `cc-figures-tables`
- "My title promises a therapy but I have no in vivo efficacy" → `cc-scope-fit` then `cc-writing-style`
- "No GEO accession yet" → `cc-ethics-registration` / `cc-submission`
- "Three reviewers, consultative cross-review" → `cc-peer-review-revision`
## Differences vs. JAMA-style clinical packs
If the work is a clinical trial or epidemiological cohort with patient-level outcomes as the core unit, a clinical-trial pack (CONSORT / STROBE / registration) fits better. Cancer Cell's unit is a **mechanism validated across systems**, not a trial endpoint.
## Worked routing example
> "We have RNA-seq showing MARK7 correlates with CAF activation in a patient cohort, plus a knockdown
> migration phenotype in one PDAC line. We want to submit to Cancer Cell."
Route it:
1. `cc-scope-fit` — a correlation + single-line phenotype is **off-fit** on both pillars; the mechanism
is not established and there is no in vivo/orthogonal validation. Gate here first.
2. `cc-study-design` — plan the missing spine: in vivo perturbation in an immunocompetent model, a
second cell system, and a mechanistic intermediate linking MARK7 to the phenotype.
3. Only once that evidence exists do `cc-reporting-standards` → `cc-statistics` → `cc-figures-tables`
apply; drafting front matter (`cc-structured-abstract`, `cc-writing-style`) before then is premature.
The router's job is to stop a promising-but-thin story from being polished into a confident desk reject.
## Stage diagnosis cues
| What the user says | Likely stage | Route |
|--------------------|--------------|-------|
| "Is this even a Cancer Cell paper?" | Pre-scope | `cc-scope-fit` |
| "Reviewers will ask about in vivo" | Design gap | `cc-study-design` |
| "My Methods feel thin" | Reporting | `cc-reporting-standards` |
| "Is n=3 wells enough?" | Statistics | `cc-statistics` |
| "The blot has no quantification" | Display | `cc-figures-tables` |
| "The Summary buries the finding" | Front matter | `cc-structured-abstract` |
| "I have no GEO accession" | Ethics/deposition | `cc-ethics-registration` |
| "Final check before upload" | Preflight | `cc-submission` |
| "Three reviewers came back" | Revision | `cc-peer-review-revision` |
## Evidence-spine manifest
Cancer Cell's unit is a mechanism validated across orthogonal systems. Track the spine as a
manifest and route on the first `MISSING`: front-matter polish is premature until cells +
in vivo + (ideally) human evidence converge on one mechanism.
```yaml
evidence_spine:
mechanism: OK | UNCLEAR # molecular intermediate linking cause -> phenotype
cell_system_1: OK | MISSING
cell_system_2: OK | MISSING # orthogonal line / method, not a technical replicate
in_vivo: OK | MISSING # perturbation in an immunocompetent model
human_data: OK | MISSING # patient cohort / clinical specimens
rigor:
key_resources_table: yes | no # cc-reporting-standards
cell_line_authenticated: yes | no
n_defined_no_pseudorep: yes | no # cc-statistics
image_quantification: yes | no # cc-figures-tables
deposition:
geo_or_pride_accession: yes | no # cc-ethics-registration
route_rule: "first MISSING/UNCLEAR above -> its listed skill; do not draft Summary/Highlights until the spine is OK"
```
## Anti-patterns
- **Do not** skip `cc-scope-fit` — editors triage on mechanism + translational fit first
- **Do not** let `cc-figures-tables` polish panels before `cc-statistics` has fixed `n` and tests
- **Do not** let `cc-peer-review-revision` draft a response before the revised experiments / text exist
- **Do not** route to front-matter polish while the in vivo or human-validation spine is still missing
- **Do not** treat a presubmission inquiry as a substitute for the scope gate — run `cc-scope-fit` regardless
---
**Source:** [`brycewang-stanford/Awesome-Journal-Skills`](https://github.com/brycewang-stanford/Awesome-Journal-Skills) → `Cancer-Cell-Skills/skills/cc-workflow/SKILL.md`
skill
liferay
Manage user roles, assign permissions, and control access to site pages and object entries within a system.